Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling treatment of both rare and highly prevalent diseases, has announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. (Frequency; Nasdaq: FREQ) and the entity formerly known as Korro Bio, Inc. (Korro Bio). The combined company will operate under the name Korro Bio, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “KRRO” on November 6, 2023.
Read the full article: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117M //
Source: https://www.globenewswire.com/news-release/2023/11/03/2773416/0/en/UPDATE-Korro-Bio-and-Frequency-Therapeutics-Announce-Closing-of-Merger-and-Private-Placement-of-117-Million.html